Ser302
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser302  -  MIG-6 (human)

Site Information
KPDYRRWsAEVTSST   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 468194

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 4 , 5 ) , mutation of modification site ( 4 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 5 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
Chk1 (human) ( 4 )
Kinases, in vitro:
Chk1 (human) ( 4 )
Treatments:
EGF ( 4 ) , metastatic potential ( 5 ) , SB218078 ( 4 ) , siRNA ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

3

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

4

Liu N, et al. (2012) Chk1 phosphorylates the tumour suppressor Mig-6, regulating the activation of EGF signalling. EMBO J 31, 2365-77
22505024   Curated Info

5

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info